YOU ARE EXPLORING
Oncology Biomarkers TMB
Cancer biomarkers | From findings to interpretation

TMB

Role of tumor mutational burden in immunotherapy interpretation, with strong dependence on platform, specimen, and tumor type.

Clinical context

Biomarker definition and clinical relevance

Tumor mutational burden (TMB) is the number of somatic mutations calculated per megabase of analyzed sequence (mut/Mb). Clinical interpretation depends on effective panel size, germline filtering, DNA quality, analysis methods, and histology. A high TMB result does not guarantee an immunotherapy response.

Note for clinicians

Final decisions depend on tumor type, stage, previous therapy, a validated assay result, and current drug indications. This content does not imply availability of a bookable laboratory service.

CLINICAL APPLICATIONS

Clinical applications and result interpretation

01

Selected tissue-agnostic indication

In 2020, the FDA granted accelerated approval for pembrolizumab in certain unresectable or metastatic solid tumors progressing after prior treatment with no satisfactory alternative, for TMB-high disease (≥10 mut/Mb using an FDA-approved test). This cutoff is not automatically transferable to every tumor or assay.

Assay and specimen: Broad, analytically and clinically validated NGS, documenting mut/Mb and the exact calculation method.

Clinical interpretation: The 10 mut/Mb threshold belongs to a specific indication; values from small panels or different algorithms may not be comparable.

02

Molecular tumor board decision support

Consider TMB together with tumor type, MSI/MMR, PD-L1, prior treatments, performance status, and other molecular features in multidisciplinary review.

Assay and specimen: Use sufficient-quality tumor DNA and document effective panel coverage.

Clinical interpretation: TMB-H has variable predictive value across cancers with different baseline immunotherapy responsiveness.

03

Understanding elevated TMB

Mismatch repair defects and mutagenic exposures can produce elevated TMB, but these biomarkers measure distinct biological features.

Assay and specimen: Obtain validated MSI/MMR testing separately when indicated.

Clinical interpretation: CAP/ASCO specifically advise against using TMB as a proxy for dMMR.

INTERPRETATION / LIMITATIONS

Limitations and interpretive notes

• Verify calculation method, panel content, germline/clonal-hematopoiesis filtering, and effective sequencing coverage.

• TMB does not directly measure the number of immunogenic neoantigens.

• Treatment decisions must follow the drug indication and evidence specific to the cancer type.

REFERENCES

Guidelines and references

Discuss a specific molecular scenario

For questions about a clinical scenario, use the support form without including any patient identifiers.

Specialist support form →
WhatsAppCall usGet expert consultation